ACM BIOLABS ANNOUNCES EXTENSIVE RESEACH COLLABORATION

Singapore, 14th August 2018 – ACM Biolabs announced that it has signed an extensive Research Collaboration Agreement with A*STAR's Singapore Immunology Network (SIgN). The collaboration is focused on using ACM Biolabs' proprietary artificial cell membrane ("ACM") technology for vaccines, primarily for oncology targets and infectious diseases prevalent in Asia. Dr. Fabien Décaillot, the lead investigator for ACM Biolabs said "We are very excited to start this collaboration and work with SIgN's outstanding researchers, including Dr. Florent Ginhoux, Dr. Lisa Ng and Dr. Katja Fink, to conduct in depth immunological studies of selected vaccine targets. In addition, the collaboration is expected to deepen our understanding of the mechanism of action which allows Artificial Cell Membrane technology to invoke such a strong antigen-specific immune response."

Dr. Peter Moran, COO of ACM Biolabs commented, "Projects such as this collaboration with SIgN help will accelerate our human program into the clinic, following in the footsteps of our lead veterinary vaccine which is progressing towards scale up and regulatory approval. The ACM platform has shown excellent results in various preclinical settings, particularly for oncology. This three-year collaboration would allow us to strengthen the platform capabilities and understanding, for example, regarding the role in T-cell activation to fight against tumours.

Dr. Fariyal Ahmed, Head Business Development and Translational Medicine commented, "This multidisciplinary collaboration with ACM Biolabs towards development of a synthetic human vaccines platform reinforces A*STAR's commitment to support the Singapore biotech start-up ecosystem."

Dr. Florent Ginhoux, Senior Principal Investigator commented, "This is a unique and exciting opportunity to collaborate very closely with ACM Biolabs. This synergistic partnership will allow us to better understand and develop Artificial Cell Membrane technologies to generate for a new platform for effective immunisations."

About ACM Biolabs Pte Ltd

ACM Biolabs is a synthetic biology company using its proprietary Artificial Cell Membrane ("ACM") technology platform to develop novel vaccines. ACM Biolabs has licensed technology from the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector agency for science, research and development, and from Nanyang Technological

University (NTU) a research-intensive University in Singapore which is consistently ranked among the world's best Universities.

AAVACC Pte Ltd is a subsidiary of ACM Biolabs focused on the development and commercialization of ACM-based veterinary vaccines, see: www.AAVACC.com.

About the Agency for Science, Technology and Research (A*STAR)

The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society.

As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by contributing to societal benefits such as improving outcomes in healthcare, urban living, and sustainability.

We play a key role in nurturing and developing a diversity of talent and leaders in our Agency and research entities, the wider research community and industry. A*STAR's R&D activities span biomedical sciences and physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.

Media Contact: info@ACMBiolabs.com